--- title: An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris nct_id: NCT04148287 overall_status: COMPLETED phase: PHASE2 sponsor: Basilea Pharmaceutica study_type: INTERVENTIONAL primary_condition: Candidemia countries: South Africa canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04148287.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04148287" ct_last_update_post_date: 2025-09-16 last_seen_at: "2026-05-12T07:26:07.685Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris **Official Title:** An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and/or Invasive Candidiasis Caused by Candida Auris **NCT ID:** [NCT04148287](https://clinicaltrials.gov/study/NCT04148287) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 9 - **Lead Sponsor:** Basilea Pharmaceutica - **Conditions:** Candidemia, Invasive Candidiases, Candida Infection - **Start Date:** 2019-12-13 - **Completion Date:** 2020-12-31 - **CT.gov Last Update:** 2025-09-16 ## Brief Summary This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in patients aged 18 years and over with limited antifungal treatment options. ## Detailed Description This is a multicenter, open-label, non-comparative, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in patients aged 18 years and over with limited antifungal treatment options. The Study Drug Treatment Period will be up to a maximum of 42 days (inclusive of the loading dose \[Study Day 1\]). There will be a Follow up Period of 4 weeks (+4 days) after EOST. The total duration of participation in the study is up to approximately 10.5 weeks (inclusive of the Screening Period \[168 hours prior to Baseline\]). ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Limited or no treatment options due to resistance, contraindication, intolerance or lack of clinical response to standard of care antifungal therapy, as advocated by the relevant regional/country treatment guidelines * Established mycological and clinical diagnosis of candidemia and/or invasive candidiasis caused by Candida auris * Able to have pre-existing intravascular catheters removed and replaced (if necessary) * Females of childbearing potential with male partners, and males with female partner(s) of childbearing potential, must agree to use 2 forms of highly effective contraception throughout the duration of the study and for 90 days following the last study drug administration. Females of childbearing potential must have a negative urine pregnancy test within 96 hours prior study entry. * Wiling to participate in the study, willing to give written informed consent, and willing to comply with the study restrictions; where permitted by local regulations, written informed consent from a legal authorized representative (LAR) will be obtained for patients who are unable to give consent Exclusion Criteria: * Life expectancy of less than 7 days in the opinion of the Investigator * Human immunodeficiency virus-infected patients who are receiving antiretroviral therapy that are moderate to strong inducers of CYP3A4, or who have detectable viremia, or who have had an active opportunistic infection within 6 months prior * Alanine aminotransferase or aspartate aminotransferase greater than or equal to 5 times the upper limit of normal * Total bilirubin greater than 3 time the upper limit of normal, unless isolated hyperbilirubinemia or due to documented Gilbert's disease * Pregnant or lactating female patient * Inappropriate fungal infection source control * Investigational drug administered within 30 days prior to dosing or five half-lives whichever is longer * Diagnosis of deep-seated Candida-related infections causing hardware associated septic arthritis, osteomyelitis, endocarditis, myocarditis, hepatosplenic candidiasis, or a central nervous system infection or site of infection that would require antifungal therapy to exceed the maximal duration of study drug treatment ``` ## Arms - **APX001** (EXPERIMENTAL) — APX001 IV or oral for up to 42 days ## Interventions - **APX001** (DRUG) — Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral. ## Primary Outcomes - **Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC)** _(time frame: EOST: any day from Day 1 up to maximum of Day 42)_ — Treatment success was defined as meeting all of the following criteria: 1\) Two consecutive blood cultures negative for Candida species, and/or for participants with a deep-seated site of infection, at least 1 negative tissue culture or aspirate/fluid culture. For participants with a deep-seated site of infection involving visceral organs from which a tissue culture was not obtainable, resolution of the attributable clinical signs of infection recorded at Baseline, and as applicable, radiological improvement associated with the site of infection. 2) Alive at EOST and 3) No concomitant use of any other systemic antifungal therapies through EOST. ## Secondary Outcomes - **Time to First Negative Blood Culture** _(time frame: Day 1 up to maximum of Day 42)_ - **Percentage of Participants With Mycological Outcomes at EOST and 2 and 4 Weeks After EOST** _(time frame: EOST: any day from Day 1 up to maximum of Day 42, 2 and 4 weeks after EOST)_ - **Percentage of Participants With Treatment Success at EOST Determined by Investigator** _(time frame: EOST: any day from Day 1 up to maximum of Day 42)_ - **Percentage of Participants With Treatment Success at 2 and 4 Weeks After EOST Determined by Investigator and by the DRC** _(time frame: 2 and 4 weeks after EOST (where EOST is any day from Day 1 up to maximum of Day 42))_ - **All-Cause Mortality Through Study Day 30** _(time frame: Day 1 through Day 30)_ - **Number of Participants With Treatment Emergent Adverse Events (TEAEs)** _(time frame: Day 1 up to maximum of 32 days of follow up post last dose of study drug, where maximum treatment duration was 42 days (maximum up to 74 days))_ ## Locations (2) - Netcare Union Hospital Trauma Surgeons, Alberton, Gauteng, South Africa - Milpark Academic Trauma Centre, Johannesburg, Gauteng, South Africa ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.netcare union hospital trauma surgeons|alberton|gauteng|south africa` — added _(2026-05-12)_ - `locations.milpark academic trauma centre|johannesburg|gauteng|south africa` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04148287.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04148287* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*